Concord Biotech Limited vs Aster DM Quality Care Limited
Last updated: 25 October 2026
Concord Biotech vs Aster DM: A MoneyDock Comparison
MoneyDock brings you a detailed comparison between two distinct players in the Indian market: Concord Biotech Limited (CONCORDBIO.NS) and Aster DM Healthcare Limited (ASTERDM.NS). While Concord Biotech operates in the pharmaceuticals and biotechnology sector, focusing on fermentation-based biopharmaceuticals, Aster DM is a prominent healthcare provider with hospitals, clinics, and pharmacies. Despite their different core operations, both companies are publicly traded on the National Stock Exchange (NSE) and represent investment opportunities within the broader healthcare and life sciences ecosystem, making a comparative analysis valuable for investors looking at sector diversification or specific growth avenues.
Key Financial Metrics Comparison
| Metric | Concord Biotech Limited | Aster DM Healthcare Limited |
|---|---|---|
| Current Price | ₹1229.30 | ₹644.75 |
| 52-Week High | ₹1579.40 | ₹869.70 |
| 52-Week Low | ₹1014.80 | ₹537.95 |
| 1-Year Return | -7.65% | 5.97% |
| Trailing P/E | N/A | N/A |
| Market Cap | N/A | N/A |
Analysis: Valuation, Returns, and Stability
Valuation: Without available Trailing P/E ratios and Market Caps for both companies, a direct valuation comparison based on these common metrics is not possible. Investors would need to delve deeper into other financial statements like revenue, earnings growth, and debt levels to form a comprehensive valuation perspective. However, looking solely at current price, Concord Biotech trades at a significantly higher price point (₹1229.30) compared to Aster DM (₹644.75). This price difference, in isolation, doesn't indicate whether one is over or undervalued without considering the underlying fundamentals and share structure.
Returns: Aster DM Healthcare clearly outperforms Concord Biotech in terms of 1-Year Returns, posting a positive 5.97% gain, whereas Concord Biotech has seen a decline of -7.65%. This suggests that Aster DM has offered better short-to-medium term capital appreciation for investors over the past year. Investors seeking recent positive momentum would find Aster DM more appealing based on this metric.
Stability: To assess stability, we can look at the proximity of the current price to their respective 52-week highs and lows. Concord Biotech's current price of ₹1229.30 is closer to its 52-week low (₹1014.80) than its high (₹1579.40), indicating a pull-back from its peak and potentially more volatility or downward pressure over the past year. Aster DM, with a current price of ₹644.75, is also trading closer to its 52-week low (₹537.95) than its high (₹869.70). However, its positive 1-year return suggests a recovery or less severe downturn compared to Concord Biotech. Both are trading off their 52-week highs, implying some market caution or correction.
MoneyDock Verdict
For Aggressive Investors: Given the negative 1-year return, Concord Biotech might be considered by aggressive investors looking for a potential bounce-back if they believe the current price represents a strong entry point after a correction. However, the lack of valuation metrics makes this a higher-risk play. Aster DM, with its positive return, could appeal to aggressive investors looking for continued momentum, though it is also off its 52-week high.
For Conservative Investors: Neither stock offers readily available P/E or Market Cap data, which are crucial for conservative analysis. However, Aster DM's positive 1-year return might make it appear marginally 'safer' in terms of recent performance compared to Concord Biotech's negative return. Conservative investors would likely hold off on both until more comprehensive valuation data is available and market stability is clearer.
For Long-Term SIP Investors: For long-term SIP investors, both companies offer exposure to vital sectors – biotech and healthcare. Aster DM has shown positive growth over the past year, which could indicate a more robust trend for consistent investment. Concord Biotech, while currently in a downturn, could be an opportunity for averaging down if one has conviction in its long-term biotech prospects. A thorough fundamental analysis beyond these price metrics is essential for long-term commitment to either.
Price data from Yahoo Finance. AI analysis by MoneyDock. Not financial advice — always do your own research before investing.